Page 6 - Wayne Koberstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.

Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”...

Companies To Watch: Lyra Therapeutics Source: Life Science Leader Follow Me On Twitter @WayneKoberstein Controlling chronic ENT conditions with precise drug elution and long action SNAPSHOT Lyra Therapeutics is a developer of therapies aimed at specific causes of ear, nose, and throat diseases. The treatments are drugs assisted by extended-release devices. Its two lead products in the development pipeline target chronic rhinosinusitis (CRS), a debilitating nasal inflammatory disease typically affecting millions of patients throughout their lifetimes, under different circumstances. One, coded ...

Synergistic COVID Therapy Development Follow Me On Twitter @WayneKoberstein When every company you never heard of says it has a product for treating COVID, it’s only natural to raise your eyebrows. But something caught my eye about this Paris-based biotech, Biophytis, when it announced an advanced-stage trial of a new drug for the most common killer of COVID patients: respiratory failure. Signing up provides unlimited access to: Trend and Leadership Articles Not yet a member of Life Science Leader? Register today. Email Login Information Business/Investment/Venture Capital/Legal Consulting ...

Continue Subscriptions Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products. Sign up for the Life Science Leader newsletter You might also want to: Sign up for the BioProcess Online Newsletter Sign up for the Clinical Leader Newsletter Sign up for the Drug Discovery Online Newsletter Sign up for the Laboratory Network.com Newsletter Sign up for the Med Device Online Newsletter Sign up for the Pharmaceutical Online Newsletter Sign up for the Outsourced Pharma Newsletter Sign up for the Biosimilar Development Newsletter...